Key result
Levosimendan protects against myocardial ischemia-reperfusion injury in diabetic rats.
Why the study?
Ischemia/reperfusion injury causes myocardial damage via oxidative, inflammatory, and apoptotic mechanisms, and the cardioprotective effects of levosimendan in diabetic myocardial ischemia/reperfusion injury remain to be examined.
Does levosimendan prevent myocardial ischemia/reperfusion injury in streptozotocin-induced diabetic rats?
Does levosimendan prevent myocardial ischemia/reperfusion injury in streptozotocin-induced diabetic rats?
Should not yet change practice in diabetic patients; leaves open levosimendan cardioprotection in human ischemia/reperfusion injury.
Objective: Ischemia/reperfusion (I/R) injury is an important cause of myocardial damage by means of oxidative, inflammatory, and apoptotic mechanisms. The aim of the present study was to examine the potential cardio protective effects of levosimendan in a diabetic rat model of myocardial I/R injury.
No takes yet. Share an insight, caveat, or question.
Kiraz et al. (2015) studied this question. Levosimendan showed cardioprotective effects against myocardial ischemia/reperfusion injury in streptozotocin-induced diabetic rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: